应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ZIOP ZIOPHARM Oncology Inc
已收盘 01-26 16:00:00 EST
0.8657
+0.0000
0.00%
最高
0.8657
最低
0.8657
成交量
0.00
今开
0.8657
昨收
0.8657
日振幅
0.00%
总市值
1.86亿
流通市值
1.49亿
总股本
2.15亿
成交额
191.08万
换手率
0.00%
流通股本
1.72亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
暂无数据
公司概况
公司名称:
ZIOPHARM Oncology Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
ZIOPHARM Oncology, Inc.最初于1998年9月在科罗拉多州注册成立。该公司是一家生物制药公司,旨在开发商业化的癌症药物组合,这种组合可以解决未满足的医疗需求。该公司的重点是许可和发展已经上市或正在开发的,与癌症治疗有关的专有的小分子候选药物,该种药物可以通过静脉和口服的方式供药。该公司为它的小分子候选药物进行了临床试用项目,包括palifosfamide ( Zymafos或ZIO - 201 ) ,indibulin ( Zybulin或ZIO -301 )和darinaparsin ( Zinapar或ZIO - 101 )。目前,该公司正在与Intrexon公司共同在癌症治疗方面寻求新的以DNA为基础的生物疗法。按照安排,公司在肿瘤研究方面有权使用Intrexon的效应平台,其中包括现有的两个临床阶段的候选产品,ZIN - CTI - 001 (或DC -RTS - IL- 12 + AL)和ZIN - ATI的使用001 (或Ad -RTS - IL- 12 + AL) 。该公司计划利用Intrexon的合成生物学平台开发产品,以刺激人体的免疫系统中用以抑制肿瘤生长和转移的主要途径,加强其小分子药物开发组合,增加病人医疗装置的科学性。有关palifosfamide ,darinaparsin和indibulin ,ZIN - CTI -001和ZIN -ATI -001的更多细节,以及其各自的临床开发计划更详细的说明,将于本报告中“Business - Product Candidates”的标题下的文字中进行介绍。
发行价格:
--
{"stockData":{"symbol":"ZIOP","market":"US","secType":"STK","nameCN":"ZIOPHARM Oncology Inc","latestPrice":0.8657,"timestamp":1643230800000,"preClose":0.8657,"halted":8,"volume":0,"delay":0,"floatShares":172416947,"shares":214635171,"eps":-0.419301,"marketStatus":"已收盘","marketStatusCode":5,"change":0,"latestTime":"01-26 16:00:00 EST","open":0.8657,"high":0.8657,"low":0.8657,"amount":1910768.562186,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.419301,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1713513600000},"symbolChange":{"newSymbol":"TCRT","executeDate":"2022-01-27"},"adr":0,"listingDate":1158897600000,"adjPreClose":0.8657,"adrRate":0,"volumeRatio":0},"requestUrl":"/m/hq/s/ZIOP?invite=TIGER026","defaultTab":"news","newsList":[],"profile":{"websiteUrl":"http://www.ziopharm.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":-0.024},{"period":"3month","weight":0.0505},{"period":"6month","weight":0.1884},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0531}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ZIOPHARM Oncology, Inc.最初于1998年9月在科罗拉多州注册成立。该公司是一家生物制药公司,旨在开发商业化的癌症药物组合,这种组合可以解决未满足的医疗需求。该公司的重点是许可和发展已经上市或正在开发的,与癌症治疗有关的专有的小分子候选药物,该种药物可以通过静脉和口服的方式供药。该公司为它的小分子候选药物进行了临床试用项目,包括palifosfamide ( Zymafos或ZIO - 201 ) ,indibulin ( Zybulin或ZIO -301 )和darinaparsin ( Zinapar或ZIO - 101 )。目前,该公司正在与Intrexon公司共同在癌症治疗方面寻求新的以DNA为基础的生物疗法。按照安排,公司在肿瘤研究方面有权使用Intrexon的效应平台,其中包括现有的两个临床阶段的候选产品,ZIN - CTI - 001 (或DC -RTS - IL- 12 + AL)和ZIN - ATI的使用001 (或Ad -RTS - IL- 12 + AL) 。该公司计划利用Intrexon的合成生物学平台开发产品,以刺激人体的免疫系统中用以抑制肿瘤生长和转移的主要途径,加强其小分子药物开发组合,增加病人医疗装置的科学性。有关palifosfamide ,darinaparsin和indibulin ,ZIN - CTI -001和ZIN -ATI -001的更多细节,以及其各自的临床开发计划更详细的说明,将于本报告中“Business - Product Candidates”的标题下的文字中进行介绍。","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.098271},{"month":2,"riseRate":0.625,"avgChangeRate":0.091033},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.01728},{"month":4,"riseRate":0.6875,"avgChangeRate":0.028507},{"month":5,"riseRate":0.5,"avgChangeRate":0.095157},{"month":6,"riseRate":0.4375,"avgChangeRate":-0.032893},{"month":7,"riseRate":0.3125,"avgChangeRate":-0.019105},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.076923},{"month":9,"riseRate":0.625,"avgChangeRate":0.062835},{"month":10,"riseRate":0.4375,"avgChangeRate":-0.025516},{"month":11,"riseRate":0.647059,"avgChangeRate":0.067971},{"month":12,"riseRate":0.294118,"avgChangeRate":-0.127992}],"exchange":"NASDAQ","name":"ZIOPHARM Oncology Inc","nameEN":"ZIOPHARM Oncology"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZIOPHARM Oncology Inc(ZIOP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ZIOPHARM Oncology Inc(ZIOP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ZIOPHARM Oncology Inc,ZIOP,ZIOPHARM Oncology Inc股票,ZIOPHARM Oncology Inc股票老虎,ZIOPHARM Oncology Inc股票老虎国际,ZIOPHARM Oncology Inc行情,ZIOPHARM Oncology Inc股票行情,ZIOPHARM Oncology Inc股价,ZIOPHARM Oncology Inc股市,ZIOPHARM Oncology Inc股票价格,ZIOPHARM Oncology Inc股票交易,ZIOPHARM Oncology Inc股票购买,ZIOPHARM Oncology Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZIOPHARM Oncology Inc(ZIOP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ZIOPHARM Oncology Inc(ZIOP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}